Sage Therapeutics (NASDAQ:SAGE) Given Neutral Rating at HC Wainwright

HC Wainwright restated their neutral rating on shares of Sage Therapeutics (NASDAQ:SAGE) in a report published on Wednesday morning, Benzinga reports. HC Wainwright currently has a $25.00 target price on the biopharmaceutical company’s stock.

Several other research analysts also recently commented on SAGE. Mizuho reduced their target price on Sage Therapeutics from $20.00 to $18.00 and set a neutral rating on the stock in a report on Friday, April 26th. Citigroup assumed coverage on Sage Therapeutics in a report on Wednesday, May 29th. They issued a sell rating and a $8.00 target price on the stock. Wedbush reissued a neutral rating and issued a $24.00 target price on shares of Sage Therapeutics in a report on Wednesday, April 17th. Oppenheimer reduced their target price on Sage Therapeutics from $25.00 to $17.00 and set a market perform rating on the stock in a report on Thursday, April 18th. Finally, Truist Financial reduced their target price on Sage Therapeutics from $22.00 to $18.00 and set a hold rating on the stock in a report on Friday, April 26th. Two investment analysts have rated the stock with a sell rating, sixteen have assigned a hold rating and three have assigned a buy rating to the stock. According to MarketBeat.com, Sage Therapeutics presently has a consensus rating of Hold and an average price target of $35.05.

Sage Therapeutics Stock Up 4.3 %

Shares of SAGE opened at $12.00 on Wednesday. The stock has a market cap of $722.16 million, a price-to-earnings ratio of -1.43 and a beta of 0.91. Sage Therapeutics has a 12 month low of $9.76 and a 12 month high of $58.06. The company has a 50-day moving average price of $12.70 and a two-hundred day moving average price of $18.90.

Sage Therapeutics (NASDAQ:SAGE) last announced its quarterly earnings results on Thursday, April 25th. The biopharmaceutical company reported ($1.80) EPS for the quarter, missing analysts’ consensus estimates of ($1.63) by ($0.17). The business had revenue of $7.90 million for the quarter, compared to the consensus estimate of $5.26 million. Sage Therapeutics had a negative return on equity of 56.81% and a negative net margin of 552.52%. The firm’s revenue for the quarter was up 139.4% on a year-over-year basis. During the same quarter in the prior year, the business earned ($2.46) EPS. Equities research analysts expect that Sage Therapeutics will post -6.46 EPS for the current fiscal year.

Institutional Trading of Sage Therapeutics

Several institutional investors and hedge funds have recently made changes to their positions in SAGE. Swiss National Bank raised its position in shares of Sage Therapeutics by 1.0% during the 3rd quarter. Swiss National Bank now owns 118,200 shares of the biopharmaceutical company’s stock valued at $2,433,000 after acquiring an additional 1,200 shares during the last quarter. Charles Schwab Investment Management Inc. grew its holdings in shares of Sage Therapeutics by 4.6% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 408,987 shares of the biopharmaceutical company’s stock valued at $8,417,000 after buying an additional 17,819 shares during the period. State of New Jersey Common Pension Fund D grew its holdings in shares of Sage Therapeutics by 161.8% in the 3rd quarter. State of New Jersey Common Pension Fund D now owns 126,693 shares of the biopharmaceutical company’s stock valued at $2,607,000 after buying an additional 78,292 shares during the period. UBS Group AG grew its holdings in shares of Sage Therapeutics by 27.8% in the 3rd quarter. UBS Group AG now owns 102,739 shares of the biopharmaceutical company’s stock valued at $2,114,000 after buying an additional 22,358 shares during the period. Finally, Citigroup Inc. grew its holdings in shares of Sage Therapeutics by 160.6% in the 3rd quarter. Citigroup Inc. now owns 176,573 shares of the biopharmaceutical company’s stock valued at $3,634,000 after buying an additional 108,814 shares during the period. Institutional investors own 99.22% of the company’s stock.

About Sage Therapeutics

Sage Therapeutics, Inc, a biopharmaceutical company, develops and commercializes brain health medicines. Its product candidates include ZULRESSO, a CIV injection for the treatment of postpartum depression (PPD) in adults; and ZURZUVAE, a neuroactive steroid, a positive allosteric modulator of GABAA receptors, targeting both synaptic and extrasynaptic GABAA receptors, for the treatment of postpartum depression.